Therapeutics

Breaking News

Lilly announced on November 23 that solanezumab missed the primary endpoint in the EXPEDITION-3 trial. Lilly will not seek marketing approval for solanezumab to treat mild AD. Earlier-stage trials are continuing.

This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.

Tools

Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Discussion

Recent Comments

  1. Kristina Capiak on Anavex 2-73

Further Reading

News

  1. Lilliputian Effect Size Fells Phase 3 Trial of Solanezumab, Leaving Its Future Uncertain
  2. Newfangled Type of Inhibitor Tricks Kinase into Turning It On
  3. Moving Toward Independence: Paralyzed Woman ‘Talks’ via Brain Implant
  4. Positive Trials of Spinal Muscular Atrophy Bode Well for Antisense Approach

Webinars

  1. Suzanne Hendrix on Constructing Composites for Trials in Early Alzheimer’s
  2. Computational Modeling—Will it Rescue AD Clinical Trials?
  3. Resolving Controversies on the Path to AD Therapeutics
  4. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources